8-K

United States

Securities and Exchange Commission

Washington, DC 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report:  June 18, 2015

Lannett Company, Inc.

(Exact Name of Registrant as Specified in its Charter)

DE	001-31298	23-0787699
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9000 State Road, Philadelphia, PA 19136

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (215) 333-9000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(d)    Election of Director

Effective July 1, 2015, Albert Paonessa, III has been appointed to the Company’s Board of Directors.

Mr. Paonessa, 55, retired from Anda, Inc., the fourth largest distributor of generic drugs in the U.S, in January 2015 after serving as President for the past 10 years.  He previously served as Anda’s Senior Vice President of Sales and before that as Vice President of IT.  Earlier, Mr. Paonessa was Vice President of Operations for VIP Pharmaceuticals, which was acquired by Anda’s parent company, Andrx, in 2000.  Mr. Paonessa earned a Bachelor of Arts degree in Interpersonal Communications from Bowling Green State University.

Mr. Paonessa will receive a grant of approximately 530 shares of Lannett common stock on July 1, 2015 in connection with his appointment.

Item 9.01   Financial Statements and Exhibits

(d)Exhibits

99.1June 24, 2015 Press Release

2

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lannett Company, Inc.
(Registrant)
By:	/s/ Arthur P. Bedrosian
Arthur P. Bedrosian
Chief Executive Officer
Dated: June 24, 2015

3

EXHIBIT INDEX

Exhibit:	Description
99.1	June 24, 2015 Press Release

4

EX-99.1

Exhibit 99.1

Contact:	Robert Jaffe
	Robert Jaffe Co., LLC
	(424) 288-4098

LANNETT NAMES ALBERT PAONESSA TO BOARD OF DIRECTORS

Philadelphia, PA — June 24, 2015 — Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Albert R. Paonessa, III, to its Board of Directors, effective July 1, 2015.  With the addition of Paonessa, the company’s Board will increase to six members, four of whom will be independent directors, including Paonessa.

Paonessa, 55, recently served as president of Anda, Inc., the fourth largest distributor of generic drugs in the U.S.  In this role, which he held for almost 10 years, Paonessa directed the company’s growth to $2 billion in revenues.  He previously served as Anda’s senior vice president of sales and before that its vice president of IT.  Earlier, Paonessa was vice president of operations for VIP Pharmaceuticals, which was acquired by Anda’s parent company Andrx in 2000.  Paonessa earned a bachelor of arts degree from Bowling Green State University.

“Albert is a well-respected generic pharmaceutical industry expert,” said Arthur Bedrosian, chief executive officer.  “He is forward thinking and brings a strong operational and technical background, especially in the areas of sales, IT, business development, planning and budgeting.  Adding his expertise will be a key strategic advantage for Lannett.”

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.  For more information, visit the company’s website at www.lannett.com.

# # #